論文・総説 - 椨　康一

分割表示 >> ／  全件表示  32 件中 1 - 32 件目

  1. Tarapongpun T, Onlamoon N, Tabu K, Chuthapisith S, Taga T. The optimized priming effect of FGF-1 and FGF-2 enhances preadipocyte lineage commitment in human adipose-derived mesenchymal stem cells. Genes to cells. 2024.03; 29 (3): 231-253. ( PubMed, DOI )

  2. Yoshitaka Murota, Mariko Nagane, Mei Wu, Mithun Santra, Seshasailam Venkateswaran, Shinji Tanaka, Mark Bradley, Tetsuya Taga, Kouichi Tabu . A niche-mimicking polymer hydrogel-based approach to identify molecular targets for tackling human pancreatic cancer stem cells Inflammation and Regeneration. 2023.09; 43 (1): 46. ( PubMed, DOI )

  3. Tabu Kouichi, Taga Tetsuya. Cancer ego-system in glioma: an iron-replenishing niche network systemically self-organized by cancer stem cells Inflammation and Regeneration. 2022.11; 42 (1): 54. ( PubMed, DOI )

  4. Wenqian Wang, Kouichi Tabu, Alapati Aimaitijiang, Tetsuya Taga. Therapy-resistant nature of cancer stem cells in view of iron metabolism Inflammation and Regeneration. 2022.11; 42 (1): 34.

  5. Yoshitaka Murota, Kouichi Tabu, Tetsuya Taga. Cancer Stem Cell-Associated Immune Microenvironment in Recurrent Glioblastomas Cells. 2022.06; 11 (13): 2054.

  6. Aimaitijiang Alapati, Tabu Kouichi, Wang Wenqian, Nobuhisa Ikuo, Taga Tetsuya. Glioma cells remotely promote erythropoiesis as a self-expanding strategy of cancer stem cells GENES TO CELLS. 2022.01; 27 (1): 25-42. ( PubMed, DOI )

  7. Suzuki I, Yoshida S, Tabu K, Kusunoki S, Matsumura Y, Izumi H, Asanoma K, Yagi H, Onoyama I, Sonoda K, Kohno K, Taga T, Takeda S, Kato K. YBX2 and cancer testis antigen 45 contribute to stemness, chemoresistance and a high degree of malignancy in human endometrial cancer Scientific Reports. 2021.02; 11 (1): 4220.

  8. Taga T and Tabu K. Glioma progression and recurrence involving maintenance and expansion strategies of glioma stem cells by organizing self-advantageous niche microenvironments. Inflammation and Regeneration. 2020.09; 40 33. ( DOI )

  9. Tabu K, Liu W, Kosaku A, Terashima K, Murota Y, Aimaitijiang A, Nobuhisa I, Hide T, Taga T. Glioma stem cell (GSC)-derived autoschizis-like products confer GSC niche properties involving M1-like tumor-associated macrophages. Stem cells (Dayton, Ohio). 2020.08; 38 (8): 921-935. ( PubMed, DOI )

  10. Tabu K, Muramatsu N, Mangani C, Wu M, Zhang R, Kimura T, Terashima K, Bizen N, Kimura R, Wang W, Murota Y, Kokubu Y, Nobuhisa I, Kagawa T, Kitabayashi I, Bradley M, and Taga T. A synthetic polymer scaffold reveals the self-maintenance strategies of rat glioma stem cells by organization of the advantageous niche. Stem Cells. 2016.05; 34 1151-1162. ( DOI )

  11. Kokubu Y, Tabu K, Wang W, Muramatsu N, Murota Y, Nobuhisa I, Jinushi M, and Taga T. Induction of protumoral CD11chigh macrophages by glioma cancer stem cells through GM-CSF. Genes to Cells. 2016.03; 21 241-251. ( DOI )

  12. Inagaki T, Kusunoki S, Tabu K, Okabe H, Yamada I, Taga T, Matsumoto A, Makino S, Takeda S, Kato K.. Up-regulation of lymphocyte antigen 6 complex expression in side-population cells derived from a human trophoblast cell line HTR-8/SVneo. Hum Cell. 2016.01; 29 10-21.

  13. Bizen N, Inoue T, Shimizu T, Tabu K, Kagawa T, Taga T. A growth-promoting signaling component cyclin D1 in neural stem cells has antiastrogliogenic function to execute self-renewal. Stem cells (Dayton, Ohio). 2014.06; 32 (6): 1602-15. ( PubMed, DOI )

  14. Kusunoki S, Kato K, Tabu K, Inagaki T, Okabe H, Kaneda H, Suga S, Terao Y, Taga T, Takeda S. The inhibitory effect of salinomycin on the proliferation, migration and invasion of human endometrial cancer stem-like cells. Gynecologic oncology. 2013.06; 129 (3): 598-605. ( PubMed, DOI )

  15. Tabu K, Bizen N, Taga T, Tanaka S. Gene Regulation of Prominin-1 (CD133) in Normal and Cancerous Tissues. Advances in experimental medicine and biology. 2013; 777 73-85. ( PubMed, DOI )

  16. Kimura T, Wang L, Tabu K, Nishihara H, Mashita Y, Kikuchi N, Tanino M, Hiraga H, Tanaka S. CD133 negatively regulates tumorigenicity via AKT pathway in synovial sarcoma. Cancer investigation. 2012.06; 30 (5): 390-7. ( PubMed, DOI )

  17. Tanino M, Kohsaka S, Kimura T, Tabu K, Nishihara H, Sawa H, Kawami H, Kamada H, Shimizu M, Tanaka S. A case of clear cell variant of solid-pseudopapillary tumor of the pancreas in an adult male patient. Annals of diagnostic pathology. 2012.04; 16 (2): 134-40. ( PubMed, DOI )

  18. Tabu K, Kimura T, Sasai K, Wang L, Bizen N, Nishihara H, Taga T, Tanaka S. Analysis of an alternative human CD133 promoter reveals the implication of Ras/ERK pathway in tumor stem-like hallmarks. Molecular cancer. 2010.02; 9 39. ( PubMed, DOI )

  19. Kimura T, Sakai M, Tabu K, Wang L, Tsunematsu R, Tsuda M, Sawa H, Nagashima K, Nishihara H, Hatakeyama S, Nakayama K, Ladanyi M, Tanaka S, Nakayama KI. Human synovial sarcoma proto-oncogene Syt is essential for early embryonic development through the regulation of cell migration. Laboratory investigation; a journal of technical methods and pathology. 2009.06; 89 (6): 645-56. ( PubMed, DOI )

  20. Tabu K, Sasai K, Kimura T, Wang L, Aoyanagi E, Kohsaka S, Tanino M, Nishihara H, Tanaka S. Promoter hypomethylation regulates CD133 expression in human gliomas. Cell research. 2008.10; 18 (10): 1037-46. ( PubMed, DOI )

  21. Nishihara H, Ozaki Y, Ito T, Yoshinaga T, Tabu K, Tanino M, Nagashima K, Tanaka S. A case of cerebral ganglioneuronal tumor in the parietal lobe of an adult. Brain tumor pathology. 2008.04; 25 (1): 45-9. ( PubMed, DOI )

  22. Wang L, Tabu K, Kimura T, Tsuda M, Linghu H, Tanino M, Kaneko S, Nishihara H, Tanaka S. Signaling adaptor protein Crk is indispensable for malignant feature of glioblastoma cell line KMG4. Biochemical and biophysical research communications. 2007.11; 362 (4): 976-81. ( PubMed, DOI )

  23. Tabu K, Ohba Y, Suzuki T, Makino Y, Kimura T, Ohnishi A, Sakai M, Watanabe T, Tanaka S, Sawa H. Oligodendrocyte lineage transcription factor 2 inhibits the motility of a human glial tumor cell line by activating RhoA. Molecular cancer research : MCR. 2007.10; 5 (10): 1099-109. ( PubMed, DOI )

  24. Sasai K, Akagi T, Aoyanagi E, Tabu K, Kaneko S, Tanaka S. O6-methylguanine-DNA methyltransferase is downregulated in transformed astrocyte cells: implications for anti-glioma therapies. Molecular cancer. 2007.06; 6 36. ( PubMed, DOI )

  25. Tabu K, Ohnishi A, Sunden Y, Suzuki T, Tsuda M, Tanaka S, Sakai T, Nagashima K, Sawa H. A novel function of OLIG2 to suppress human glial tumor cell growth via p27Kip1 transactivation. Journal of cell science. 2006.04; 119 (Pt 7): 1433-41. ( PubMed, DOI )

  26. Asanuma T, Inanami O, Tabu K, Waki K, Kon Y, Kuwabara M. Protection against malonate-induced ischemic brain injury in rat by a cell-permeable peptidic c-Jun N-terminal kinase inhibitor, (L)-HIV-TAT48-57-PP-JBD20, observed by the apparent diffusion coefficient mapping magnetic resonance imaging method. Neuroscience letters. 2004.04; 359 (1-2): 57-60. ( PubMed, DOI )

  27. 椨康一, 田賀哲也. 合成ポリマーを用いた癌幹細胞ニッチの特性解明 別冊・医学のあゆみ「治療標的としてのがん幹細胞」. 2021.03; 122-126.

  28. 椨 康一, 田賀 哲也. 【脳・神経疾患治療の最前線】研究者の最新動向「膠芽腫がん幹細胞ニッチの標的探索」 Precision Medicine. 2020.10; 3 (11): 70-73.

  29. 椨 康一, 田賀 哲也. 【治療標的としてのがん幹細胞】がん幹細胞の理解に向けた新技術開発とその応用「合成ポリマーを用いたがん幹細胞ニッチの解析」 医学のあゆみ. 2020.05; 273 (5): 474-479. ( 医中誌 )

  30. 椨康一, 田賀哲也. 【悪性脳腫瘍の基礎～臨床的アプローチ】Cutting Edge「ニッチを標的とする膠芽腫がん幹細胞の制御」 Medical Science Digest. 2020.05; 46 (8): 77-79.

  31. 椨康一、田賀哲也. がん幹細胞によるがん進展メカニズム 次世代がん治療. 2017.06; 51-57.

  32. 椨康一、室田吉貴、田賀哲也. 【バイオマテリアルを基盤とした生命科学研究(Materials-based biology)】 合成ポリマーを用いた癌幹細胞ニッチの特性解明 バイオマテリアル -生体材料-. 2017.01; 35 (1): 42-45.

< 前のページ - 次のページ >

  • 1
このページの先頭へ▲